Precision-Guided (MALT-Targeting) Mucosal Vaccines
This handout was given to attendees at the World Vaccine Congress, March 30-April 2, 2026:
PRECISION-GUIDED VACCINES LLC
Our YOU CHOOSE THE ANTIGEN offer:
1. You specify the antigen; we don’t need to know sequence, type of pathogen, or intended
animals
2. You must be fully capable of – and must commit to – completing pathogen challenge tests in rats
or larger within 4 months after receiving phages
3. T7 phages will have 3 best MALT-targeting sequences in tandem, double-glycine linkers
between them, in 10B capsid proteins (~40 copies/particle)
4. 400 copies of your antigen, in 10A proteins
5. Phage suspension pure enough for direct infusion of droplets into animal nostrils
6. $4000 total for first 10 purchasers (50% up front). If you provide monoclonals for dot-blot
confirmation during preparation, price will drop to $3750
7. Unlimited right to grow phages for in-house testing
8. Purchase will lock in a right to worldwide exclusive license to all MALT-targeting technology, at
royalty not to exceed 8%, for first company that generates sufficient data to enable USDA
registration for that pathogen, in that class of animals, regardless of antigen sequence,
particle type, or other details. That right will also include worldwide sublicensing rights, and
our royalty cut will not exceed 30% (since sublicensing usually creates pure-profit income
with no substantial expenses, sublicensing splits of 50-50 are common. We'll limit ourselves
to 30%, but only for the first 10 transactions).